The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Afatinib (Afa) + bevacizumab (Bev) versus afatinib alone as first-line treatment of patients with EGFR-mutated advanced non-squamous NSCLC: Primary analysis of the multicenter, randomized, phase II study—AfaBev-CS study.
 
Nobuhisa Ishikawa
Speakers' Bureau - Boehringer Ingelheim
 
Takashi Ninomiya
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma
 
Toshiyuki Kozuki
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Shoichi Kuyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; Lilly Japan; MSD; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
 
Koji Inoue
No Relationships to Disclose
 
Toshihide Yokoyama
Honoraria - AstraZeneca; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb Co. Ltd. (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); MSD K.K (Inst); PAREXEL International Inc. (Inst); Takeda (Inst)
 
Nobuhiro Kanaji
No Relationships to Disclose
 
Masayuki Yasugi
No Relationships to Disclose
 
Takuo Shibayama
Honoraria - AstraZeneca Japan; Daiichi Sankyo; Nippon Boehringer Ingelheim
 
Keisuke Aoe
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; Bristol-Myers Squibb Japan; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer
 
Nobuaki Ochi
No Relationships to Disclose
 
Kazunori Fujitaka
No Relationships to Disclose
 
Masahiro Kodani
No Relationships to Disclose
 
Yutaka Ueda
No Relationships to Disclose
 
Kazuhiko Watanabe
No Relationships to Disclose
 
Akihiro Bessho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Pfizer (Inst)
 
Keisuke Sugimoto
No Relationships to Disclose
 
Isao Oze
No Relationships to Disclose
 
Katsuyuki Kiura
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyorin (Inst); Merck (Inst); MSD (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)